Paper25754814
Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity.
Lauber K and 6 others. Cancer Lett, 2015. Cited by 52 papers, by iCite.
Cite this record
ConductScience Library. Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity. Papers, record 25754814. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25754814
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| HSP90 Heat-Shock Proteins | Major topic |
| Heat-Shock Response | Major topic |
| Hyperthermia, Induced | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Cell Death | |
| Combined Modality Therapy | |
| Heat-Shock Proteins | |
| Humans |
Source PubMed
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41375025 | Temperature-Dependent Effects of Induced Hyperthermia, Including Whole-Body Hyperthermia, on the Hallmarks of Cancer: A Systematic Review. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41375025 | PubMed |
| 41269528 | Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses. | EJNMMI Res | 2025 | https://conductscience.org/library/papers/41269528 | PubMed |
| 39416669 | Multifunctional gold nanoparticles for cancer theranostics. | 3 Biotech | 2024 | https://conductscience.org/library/papers/39416669 | PubMed |
| 38067348 | Efficient Radial-Shell Model for 3D Tumor Spheroid Dynamics with Radiotherapy. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38067348 | PubMed |
| 37986165 | Machine learning-based analysis of cancer cell-derived vesicular proteins revealed significant tumor-specificity and predictive potential of extracellular vesicles for cell invasion and proliferation - A meta-analysis. | Cell Commun Signal | 2023 | https://conductscience.org/library/papers/37986165 | PubMed |
| 37794000 | Myoglobin-loaded gadolinium nanotexaphyrins for oxygen synergy and imaging-guided radiosensitization therapy. | Nat Commun | 2023 | https://conductscience.org/library/papers/37794000 | PubMed |
| 36422293 | Natural Products Targeting Hsp90 for a Concurrent Strategy in Glioblastoma and Neurodegeneration. | Metabolites | 2022 | https://conductscience.org/library/papers/36422293 | PubMed |
| 35043518 | HSP90 promotes radioresistance of cervical cancer cells via reducing FBXO6-mediated CD147 polyubiquitination. | Cancer Sci | 2022 | https://conductscience.org/library/papers/35043518 | PubMed |
| 34986545 | Abscopal effect in the radio and immunotherapy. | Radiat Oncol J | 2021 | https://conductscience.org/library/papers/34986545 | PubMed |
| 33816244 | Inhibition of HSP90 as a Strategy to Radiosensitize Glioblastoma: Targeting the DNA Damage Response and Beyond. | Front Oncol | 2021 | https://conductscience.org/library/papers/33816244 | PubMed |
| 33053689 | Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/33053689 | PubMed |
| 33005832 | The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure. | Bioact Mater | 2021 | https://conductscience.org/library/papers/33005832 | PubMed |
| 32984042 | Priming of Anti-tumor Immune Mechanisms by Radiotherapy Is Augmented by Inhibition of Heat Shock Protein 90. | Front Oncol | 2020 | https://conductscience.org/library/papers/32984042 | PubMed |
| 32640548 | Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32640548 | PubMed |
| 32340275 | Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32340275 | PubMed |
| 32099495 | Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives. | Lung Cancer (Auckl) | 2019 | https://conductscience.org/library/papers/32099495 | PubMed |
| 32015396 | 3D tumour spheroids for the prediction of the effects of radiation and hyperthermia treatments. | Sci Rep | 2020 | https://conductscience.org/library/papers/32015396 | PubMed |
| 31776398 | A cellular automaton model for spheroid response to radiation and hyperthermia treatments. | Sci Rep | 2019 | https://conductscience.org/library/papers/31776398 | PubMed |
| 31540530 | Cellular Stress Responses in Radiotherapy. | Cells | 2019 | https://conductscience.org/library/papers/31540530 | PubMed |
| 31500898 | Focused Ultrasound-Mediated Hyperthermia in Vitro: An Experimental Arrangement for Treating Cells under Tissue-Mimicking Conditions. | Ultrasound Med Biol | 2019 | https://conductscience.org/library/papers/31500898 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25754814
GET https://conductscience.org/api/papers/v1/25754814/cited_by?page=2